{"id":"cefazolin-and-moxifloxacin","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Hypersensitivity/allergic reaction (cefazolin)"},{"rate":"0.3-1%","effect":"Tendinopathy (moxifloxacin)"},{"rate":"0.1-1%","effect":"QT prolongation (moxifloxacin)"},{"rate":"3-10%","effect":"Gastrointestinal disturbance"},{"rate":"0.5-2%","effect":"Photosensitivity (moxifloxacin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin is a first-generation cephalosporin that binds penicillin-binding proteins and prevents peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Moxifloxacin is a fourth-generation fluoroquinolone that inhibits bacterial topoisomerases, preventing DNA replication and transcription. Together, they provide synergistic coverage against gram-positive and gram-negative bacteria, likely being evaluated for surgical prophylaxis or serious infections.","oneSentence":"This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and moxifloxacin (a fluoroquinolone) to inhibit bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum antimicrobial coverage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:12.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis (likely indication given Phase 3 status and combination rationale)"},{"name":"Serious gram-positive and gram-negative bacterial infections"}]},"trialDetails":[{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT05162625","phase":"PHASE2","title":"Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2021-12-10","conditions":"Endophthalmitis, Open Globe Injury, Moxifloxacin","enrollment":100},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT00323219","phase":"PHASE3","title":"Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2004-01","conditions":"Cellulitis","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cefazolin and Moxifloxacin","genericName":"Cefazolin and Moxifloxacin","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and moxifloxacin (a fluoroquinolone) to inhibit bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum antimicrobial coverage. Used for Surgical site infection prophylaxis (likely indication given Phase 3 status and combination rationale), Serious gram-positive and gram-negative bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}